1. Home
  2. TLSA vs KZIA Comparison

TLSA vs KZIA Comparison

Compare TLSA & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

N/A

Current Price

$0.68

Market Cap

145.1M

Sector

Health Care

ML Signal

N/A

Logo Kazia Therapeutics Limited

KZIA

Kazia Therapeutics Limited

N/A

Current Price

$5.36

Market Cap

125.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
TLSA
KZIA
Founded
2013
1994
Country
United Kingdom
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
145.1M
125.6M
IPO Year
2017
2002

Fundamental Metrics

Financial Performance
Metric
TLSA
KZIA
Price
$0.68
$5.36
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
9
Target Price
$7.87
★ $27.22
AVG Volume (30 Days)
★ 522.3K
241.7K
Earning Date
05-01-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$258.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.55
$4.86
52 Week High
$1.90
$17.40

Technical Indicators

Market Signals
Indicator
TLSA
KZIA
Relative Strength Index (RSI) 46.12 28.38
Support Level $0.57 $4.86
Resistance Level $1.21 $14.85
Average True Range (ATR) 0.10 0.68
MACD 0.01 -0.16
Stochastic Oscillator 55.24 9.86

Price Performance

Historical Comparison
TLSA
KZIA

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

About KZIA Kazia Therapeutics Limited

Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.

Share on Social Networks: